SCHEMBL3209442

SCHEMBL3209442

CN(C)C(=O)c1ccc(N(Cc2cncs2)c2ccc(OC(F)F)c(OC(F)F)c2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 5/20 0.43
PDE4D Q08499 6/20 0.36
PDE4B Q07343 5/20 0.36
PDE4C Q08493 4/20 0.36
PDK1 Q15118 4/20 0.33
PDK2 Q15119 2/20 0.33
PDK3 Q15120 2/20 0.33
PDK4 Q16654 2/20 0.33
JAK2 O60674 1/20 0.33
JAK1 P23458 1/20 0.33
HSP90AA1 P07900 1/20 0.33
HSP90AB1 P08238 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
TRPM8 Q7Z2W7 1/20 0.33
PARP15 Q460N3 1/20 0.33
PARP10 Q53GL7 1/20 0.33
HRH4 Q9H3N8 1/20 0.33
HTT P42858 2/20 0.32
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3203145 0.90 PDE4D (0.37) PDE4APDE4DPDE4BPDE4CTRPM8
SCHEMBL3122844 0.89 PDE4A (0.40) PDE4APDE4DPDE4BPDE4CPARP15
SCHEMBL3191879 0.88 PARP15 (0.46) PDE4APDE4DPDE4BPDE4CTRPM8
SCHEMBL3200150 0.87 PDE4B (0.35) PDE4APDE4DPDE4BPDE4CPDK1
SCHEMBL3193291 0.87 PCSK9 (0.39) PDE4APDE4DPDE4BPDE4CTRPM8
SCHEMBL3125745 0.87 RXRA (0.48) PDE4APDE4DPDE4BPDE4CRXRA
SCHEMBL3126060 0.86 HDAC6 (0.37) PDE4APDE4DPDE4BPDE4CTRPM8
SCHEMBL3131039 0.85 RXRA (0.39) PDE4APDE4DPDE4BPDE4CPARP15
SCHEMBL3125356 0.85 RXRA (0.39) PDE4APDE4DPDE4BPDE4CHTT
SCHEMBL3125660 0.84 RXRA (0.42) TRPM8HRH4HTTRAB9ARXRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US claimed
WO-2010003084-A2 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-01-07 WO claimed
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
WO-2010003084-A2 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS PDE4A, PDE4B, PDE3B PDE4A 1/4885PDE4D 9/4885PDE4B 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.